

Mutations in *CIC* and *FUBP1* Contribute to

Science

333, 1453-1455

DOI: [10.1126/science.1210557](https://doi.org/10.1126/science.1210557)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Astrocytic and Oligodendroglial Tumors. , 2010, , 63-102.		4
2	ATXN1 Protein Family and CIC Regulate Extracellular Matrix Remodeling and Lung Alveolarization. <i>Developmental Cell</i> , 2011, 21, 746-757.	3.1	89
3	Unraveling the Glioma Epigenomeâ€”From Molecular Mechanisms to Novel Biomarkers and Therapeutic Targets. <i>Brain Pathology</i> , 2011, 21, 619-632.	2.1	38
4	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 21188-21193.	3.3	585
5	Oligodendrogliomas. <i>Current Opinion in Oncology</i> , 2012, 24, 687-693.	1.1	24
6	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. <i>Neuro-Oncology</i> , 2012, 14, iv100-iv108.	0.6	154
7	The Capicua repressor â€”a general sensor of RTK signaling in development and disease. <i>Journal of Cell Science</i> , 2012, 125, 1383-1391.	1.2	141
8	Torso RTK controls Capicua degradation by changing its subcellular localization. <i>Development (Cambridge)</i> , 2012, 139, 3962-3968.	1.2	56
9	CIC and FUBP1 Mutations in Oligodendroglioma. <i>Neurosurgery</i> , 2012, 70, N22-N23.	0.6	4
10	Mapping genes for oligodendroglioma. <i>Personalized Medicine</i> , 2012, 9, 311-313.	0.8	0
11	Primary brain tumours in adults. <i>Lancet, The</i> , 2012, 379, 1984-1996.	6.3	723
12	Cancer genomics and pathology: <i>All Together Now</i>. <i>Pathology International</i> , 2012, 62, 647-659.	0.6	6
13	Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. <i>Acta Neuropathologica</i> , 2012, 124, 615-625.	3.9	376
14	Delving into somatic variation in sporadic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 155-170.	1.5	35
15	<i>IDH1</i> and <i>IDH2</i> Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives. <i>Clinical Cancer Research</i> , 2012, 18, 5562-5571.	3.2	341
16	Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity. <i>Acta Neuropathologica</i> , 2012, 124, 627-641.	3.9	143
17	iTRAQ-based quantitative proteomic analysis for identification of oligodendroglioma biomarkers related with loss of heterozygosity on chromosomal arm 1p. <i>Journal of Proteomics</i> , 2012, 77, 480-491.	1.2	16
18	The newcomer in the integrin family: Integrin Î±9 in biology and cancer. <i>Advances in Biological Regulation</i> , 2012, 52, 326-339.	1.4	55

#	ARTICLE	IF	CITATIONS
19	Genetics of adult glioma. <i>Cancer Genetics</i> , 2012, 205, 613-621.	0.2	737
20	<i>KIAA1549</i> and <i>BRAF</i> Fusions and IDH Mutations Can Coexist in Diffuse Gliomas of Adults. <i>Brain Pathology</i> , 2012, 22, 841-847.	2.1	55
21	EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 20-26.	2.2	0
22	Biomarkers Classification and Therapeutic Decision-Making for Malignant Gliomas. <i>Current Treatment Options in Oncology</i> , 2012, 13, 417-436.	1.3	25
23	Downregulation of <i>PRDX1</i> by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro. <i>Oncogene</i> , 2012, 31, 3409-3418.	2.6	38
24	SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas. <i>PLoS ONE</i> , 2012, 7, e45950.	1.1	25
25	Frequent <i>ATRX</i> , <i>CIC</i> , <i>FUBP1</i> and <i>IDH1</i> mutations refine the classification of malignant gliomas. <i>Oncotarget</i> , 2012, 3, 709-722.	0.8	532
26	Concurrent <i>CIC</i> mutations, <i>IDH</i> mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. <i>Journal of Pathology</i> , 2012, 226, 7-16.	2.1	272
27	Emerging insights into the molecular and cellular basis of glioblastoma. <i>Genes and Development</i> , 2012, 26, 756-784.	2.7	463
28	DNA hypermethylation and 1p Loss silence <i>NHEJ1</i> in oligodendroglioma. <i>Annals of Neurology</i> , 2012, 71, 845-849.	2.8	22
29	Recent advances in the molecular understanding of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2012, 108, 11-27.	1.4	358
30	Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 302-307.	2.0	21
31	<i>CIC</i> and <i>FUBP1</i> mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. <i>Acta Neuropathologica</i> , 2012, 123, 853-860.	3.9	130
32	Mutual Repression by Bantam miRNA and Capicua Links the EGFR/MAPK and Hippo Pathways in Growth Control. <i>Current Biology</i> , 2012, 22, 651-657.	1.8	81
33	Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 271-291.	1.8	97
34	Recurrent <i>PIK3CA</i> mutations in rosette-forming glioneuronal tumor. <i>Acta Neuropathologica</i> , 2012, 123, 285-287.	3.9	57
35	Integrated analysis of recurrent properties of cancer genes to identify novel drivers. <i>Genome Biology</i> , 2013, 14, R52.	13.9	33
36	The Genetics of Melanoma: Recent Advances. <i>Annual Review of Genomics and Human Genetics</i> , 2013, 14, 257-279.	2.5	66

#	ARTICLE	IF	CITATIONS
37	Progress on molecular biomarkers and classification of malignant gliomas. <i>Frontiers of Medicine</i> , 2013, 7, 150-156.	1.5	21
38	Contribution of Molecular Biology to the Classification of Low-Grade Diffuse Glioma. , 2013, , 61-72.		0
39	Cellular Origin of Grade II Gliomas. , 2013, , 75-89.		1
40	Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. <i>BMC Genomics</i> , 2013, 14, 505.	1.2	30
41	Anaplastic Oligodendroglioma: A New Treatment Paradigm and Current Controversies. <i>Current Treatment Options in Oncology</i> , 2013, 14, 505-513.	1.3	16
42	Molecular neuro-oncology in clinical practice: a new horizon. <i>Lancet Oncology</i> , The, 2013, 14, e370-e379.	5.1	167
43	Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. <i>Acta Neuropathologica</i> , 2013, 126, 277-289.	3.9	49
44	Epidemiology of Diffuse Low-Grade Gliomas. , 2013, , 9-30.		5
45	Identification of hidden relationships from the coupling of Hydrophobic Cluster Analysis and Domain Architecture information. <i>Bioinformatics</i> , 2013, 29, 1726-1733.	1.8	29
47	Anaplastic oligodendrogliomasâ€™ value of early chemotherapy. <i>Nature Reviews Neurology</i> , 2013, 9, 7-8.	4.9	3
48	Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. <i>Journal of Clinical Oncology</i> , 2013, 31, 337-343.	0.8	968
49	Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing. <i>Science Translational Medicine</i> , 2013, 5, 197ra102.	5.8	220
50	cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome. <i>Journal of Neuro-Oncology</i> , 2013, 115, 249-259.	1.4	28
51	First Proteomic Exploration of Protein-Encoding Genes on Chromosome 1 in Human Liver, Stomach, and Colon. <i>Journal of Proteome Research</i> , 2013, 12, 67-80.	1.8	20
52	Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. <i>Acta Neuropathologica</i> , 2013, 126, 267-276.	3.9	315
53	<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6021-6026.	3.3	1,202
54	Oral BG12 for treatment of relapsingâ€™remitting MS. <i>Nature Reviews Neurology</i> , 2013, 9, 8-10.	4.9	17
55	The Definition of Primary and Secondary Glioblastoma. <i>Clinical Cancer Research</i> , 2013, 19, 764-772.	3.2	819

#	ARTICLE	IF	CITATIONS
56	Genetics and pharmacogenomics of diffuse gliomas. , 2013, 137, 78-88.		7
57	Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management. Cancer Letters, 2013, 331, 139-146.	3.2	228
58	Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature Genetics, 2013, 45, 12-17.	9.4	374
59	Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations in RET and RAS. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E364-E369.	1.8	213
60	Modulation of the Wnt/beta-catenin pathway in human oligodendrogloma cells by Sox17 regulates proliferation and differentiation. Cancer Letters, 2013, 335, 361-371.	3.2	42
61	Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nature Genetics, 2013, 45, 602-612.	9.4	704
62	<i><scp>IDH1</scp></i> Mutations in Oligodendroglial Tumors: Comparative Analysis of Direct Sequencing, Pyrosequencing, Immunohistochemistry, Nested <scp>PCR</scp> and <scp>PNA</scp>â€Mediated Clamping <scp>PCR</scp>. Brain Pathology, 2013, 23, 285-293.	2.1	28
63	What do we know about IDH1/2 mutations so far, and how do we use it?. Acta Neuropathologica, 2013, 125, 621-636.	3.9	133
64	Analysis of <scp><i>CIC</i></scp>â€associated <scp>CpG</scp> island methylation in oligoastrocytoma. Neuropathology and Applied Neurobiology, 2013, 39, 831-836.	1.8	1
65	Far upstream element binding protein 1: a commander of transcription, translation and beyond. Oncogene, 2013, 32, 2907-2916.	2.6	96
67	Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendroglomas and High-Grade Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2013, 72, 298-306.	0.9	51
68	Capicua regulates proliferation and survival of RB-deficient cells in Drosophila. Biology Open, 2013, 2, 183-190.	0.6	7
69	Molecular genetics of low-grade gliomas: genomic alterations guiding diagnosis and therapeutic intervention. 11th Annual Frye-Halloran Brain Tumor Symposium. Neurosurgical Focus, 2013, 34, E9.	1.0	10
70	Promoter Hypermethylation of the<i>EMP3</i>Gene in a Series of 229 Human Gliomas. BioMed Research International, 2013, 2013, 1-11.	0.9	15
72	Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia. PLoS Genetics, 2013, 9, e1003997.	1.5	110
73	The molecular landscape of diffuse glioma and prospects for biomarker development. Expert Opinion on Medical Diagnostics, 2013, 7, 573-587.	1.6	9
74	Next-generation molecular genetics of brain tumours. Current Opinion in Neurology, 2013, 26, 681-687.	1.8	15
75	The Molecular Pathology of Primary Brain Tumors. , 2013, 18, 210-220.		0

#	ARTICLE	IF	CITATIONS
76	Predictive biomarkers in adult gliomas. <i>Current Opinion in Oncology</i> , 2013, 25, 689-694.	1.1	34
77	Kinetics of gene derepression by ERK signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 10330-10335.	3.3	51
78	Molecular biomarkers in pediatric glial tumors. <i>Current Opinion in Oncology</i> , 2013, 25, 665-673.	1.1	14
79	Far upstream element-binding protein 1 and RNA secondary structure both mediate second-step splicing repression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E2687-95.	3.3	35
80	From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. <i>Neurosurgical Focus</i> , 2013, 34, E2.	1.0	59
81	Minding the Ps and Qs: Perseverance and Quality Studies Lead to Major Advances in Patients With Anaplastic Oligodendroglioma. <i>Journal of Clinical Oncology</i> , 2013, 31, 299-300.	0.8	4
82	Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management. <i>CNS Oncology</i> , 2013, 2, 351-358.	1.2	10
83	Far Upstream Element-Binding Protein 1 (FUBP1) is Overexpressed in Human Gastric Cancer Tissue Compared to Non-Cancerous Tissue. <i>Onkologie</i> , 2013, 36, 650-655.	1.1	22
84	Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain areas. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 31-34.	0.3	11
85	A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1. <i>PLoS ONE</i> , 2013, 8, e59773.	1.1	39
86	Novel CIC Point Mutations and an Exon-Spanning, Homozygous Deletion Identified in Oligodendroglial Tumors by a Comprehensive Genomic Approach Including Transcriptome Sequencing. <i>PLoS ONE</i> , 2013, 8, e76623.	1.1	16
87	The Distribution and Significance of IDH Mutations in Gliomas. , 0, , .		5
88	Genetic Profiling: Searching for Novel Genetic Aberrations in Glioblastoma. , 0, , .		0
89	Prognostic and Predictive Biomarkers in Adult and Pediatric Gliomas: Toward Personalized Treatment. <i>Frontiers in Oncology</i> , 2014, 4, 47.	1.3	36
90	Far upstream element-binding protein 1(FUBP1) expression differs between human colorectal cancer and non-cancerous tissue. <i>Neoplasma</i> , 2014, 62, 533-540.	0.7	12
91	The genetic landscape of anaplastic astrocytoma. <i>Oncotarget</i> , 2014, 5, 1452-1457.	0.8	69
92	Quantitative iTRAQ LC-MS/MS Proteomics Reveals Transcription Factor Crosstalk and Regulatory Networks in Hypopharyngeal Squamous Cell Carcinoma. <i>Journal of Cancer</i> , 2014, 5, 525-536.	1.2	21
93	Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 439-452.	1.5	69

#	ARTICLE	IF	CITATIONS
94	In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies. Cellular and Molecular Life Sciences, 2014, 71, 4007-4026.	2.4	42
95	Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas. Genome Biology, 2014, 15, 471.	3.8	29
96	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	5.8	3,665
97	Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas. Journal of Neuro-Oncology, 2014, 120, 283-291.	1.4	7
98	FBP1 Is an Interacting Partner of Menin. International Journal of Endocrinology, 2014, 2014, 1-6.	0.6	5
99	Downregulation of CIC Does Not Associate with Overexpression of ETV1 or MAP Kinase Pathway Activation in Gastrointestinal Stromal Tumors. Cancer Investigation, 2014, 32, 363-367.	0.6	2
100	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncology, 2014, 16, 1630-1638.	0.6	77
101	Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. Genes Chromosomes and Cancer, 2014, 53, 15-24.	1.5	91
102	Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. Neurosurgical Focus, 2014, 37, E13.	1.0	48
103	A new der(1;7)(q10;p10) leading to a singular 1p loss in a case of glioblastoma with oligodendroglioma component. Neuropathology, 2014, 34, 170-178.	0.7	3
104	Distinct transcriptional signature and immunoprofile of <i>CIC</i> – <i>UX4</i> fusion–positive round cell tumors compared to <i>EWSR1</i> –rearranged ewing sarcomas: Further evidence toward distinct pathologic entities. Genes Chromosomes and Cancer, 2014, 53, 622-633.	1.5	201
105	A review of ELTD1, a pro-angiogenic adhesion GPCR. Biochemical Society Transactions, 2014, 42, 1658-1664.	1.6	25
106	Low-Grade Gliomas. Oncologist, 2014, 19, 403-413.	1.9	192
107	Cell transcriptional state alters genomic patterns of DNA double-strand break repair in human astrocytes. Nature Communications, 2014, 5, 5799.	5.8	12
108	TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL. Neuro-Oncology, 2014, 16, iii5-iii6.	0.6	8
109	Generation and Sequencing of Pulmonary Carcinoid Tumor Cell Lines. Journal of Thoracic Oncology, 2014, 9, 1763-1771.	0.5	8
110	Exome Sequencing Reveals the Likely Involvement of SOX10 in Uveal Melanoma. Optometry and Vision Science, 2014, 91, e185-e192.	0.6	6
111	Molecular Genetics of Gliomas. Cancer Journal (Sudbury, Mass), 2014, 20, 66-72.	1.0	93

#	ARTICLE	IF	CITATIONS
112	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. <i>Neuro-Oncology</i> , 2014, 16, 81-91.	0.6	370
113	NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes. Database: the Journal of Biological Databases and Curation, 2014, 2014, bau015.	1.4	50
114	Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas. <i>Neuro-Oncology</i> , 2014, 16, 1100-1109.	0.6	44
115	Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. <i>Modern Pathology</i> , 2014, 27, 332-342.	2.9	45
116	Signals that regulate the oncogenic fate of neural stem cells and progenitors. <i>Experimental Neurology</i> , 2014, 260, 56-68.	2.0	15
117	Alpha-internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion. <i>Brain Tumor Pathology</i> , 2014, 31, 257-264.	1.1	10
118	Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas. <i>Neuro-Oncology</i> , 2014, 16, 400-408.	0.6	13
119	Molecular Testing in Cancer. , 2014, , .		2
120	Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 2898-2909.	3.2	146
121	The epidemiology of glioma in adults: a "state of the science" review. <i>Neuro-Oncology</i> , 2014, 16, 896-913.	0.6	1,586
122	Pathology of Gliomas and Developments in Molecular Testing. <i>Clinical Oncology</i> , 2014, 26, 377-384.	0.6	5
123	Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 205-216.	1.8	41
124	The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse Glioma. <i>Clinical Cancer Research</i> , 2014, 20, 5601-5611.	3.2	53
126	Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective. <i>Journal of Neuro-Oncology</i> , 2014, 119, 481-490.	1.4	20
127	Genetic Markers in Adult High-Grade Gliomas. <i>Seminars in Radiation Oncology</i> , 2014, 24, 235-239.	1.0	2
128	TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. <i>British Journal of Cancer</i> , 2014, 111, 2024-2032.	2.9	158
129	Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop. <i>Neuro-Oncology</i> , 2014, 16, 173-178.	0.6	23
130	Isocitrate dehydrogenase 1 and 2 mutations in gliomas. <i>Journal of Neuroscience Research</i> , 2014, 92, 1611-1620.	1.3	18

#	ARTICLE	IF	CITATIONS
131	Next generation sequencing in nonsyndromic intellectual disability: From a negative molecular karyotype to a possible causative mutation detection. American Journal of Medical Genetics, Part A, 2014, 164, 170-176.	0.7	34
132	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology, 2014, 16, 1541-1546.	0.6	12
133	Metastatic tumor evolution and organoid modeling implicate TGFBR2as a cancer driver in diffuse gastric cancer. Genome Biology, 2014, 15, 428.	3.8	110
134	Molecular Neuro-oncology and the Challenge of the Blood-Brain Barrier. Seminars in Oncology, 2014, 41, 438-445.	0.8	12
135	Molecular and genetic pathways in gliomas: the future of personalized therapeutics. CNS Oncology, 2014, 3, 123-136.	1.2	22
137	The Transcriptional Regulatory Network of Proneural Glioma Determines the Genetic Alterations Selected during Tumor Progression. Cancer Research, 2014, 74, 1440-1451.	0.4	48
138	Medical therapy of gliomas. Journal of Neuro-Oncology, 2014, 119, 503-512.	1.4	15
139	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 2014, 128, 561-571.	3.9	176
140	Evaluation of a target region capture sequencing platform using monogenic diabetes as a study-model. BMC Genetics, 2014, 15, 13.	2.7	51
141	Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH1. Journal of Clinical Oncology, 2014, 32, 783-790.	0.8	356
142	Sox2 Is Required to Maintain Cancer Stem Cells in a Mouse Model of High-Grade Oligodendroglioma. Cancer Research, 2014, 74, 1833-1844.	0.4	84
143	The Splicing Factor FUBP1 Is Required for the Efficient Splicing of Oncogene MDM2 Pre-mRNA. Journal of Biological Chemistry, 2014, 289, 17350-17364.	1.6	32
144	Expression of Hedgehog ligand and signal transduction components in mutually distinct isocitrate dehydrogenase mutant glioma cells supports a role for paracrine signaling. Journal of Neuro-Oncology, 2014, 119, 243-251.	1.4	6
145	Glial Progenitors as Targets for Transformation in Glioma. Advances in Cancer Research, 2014, 121, 1-65.	1.9	38
146	An overview of current and future treatment options for adults anaplastic oligodendroglial tumors. Expert Opinion on Orphan Drugs, 2014, 2, 831-840.	0.5	0
147	Genetics and epigenetics of gliomas. Swiss Medical Weekly, 2014, 144, w14018.	0.8	7
148	Clinical Discussion of the Management of Anaplastic Oligodendroglioma/Oligoastrocytoma (Both) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 665-672.	2.3	11
149	Glioma. Nature Reviews Disease Primers, 2015, 1, 15017.	18.1	718

#	ARTICLE	IF	CITATIONS
150	Pathology and Genetics of Diffuse Gliomas in Adults. <i>Neurologia Medico-Chirurgica</i> , 2015, 55, 28-37.	1.0	16
151	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. <i>Acta Neuropathologica Communications</i> , 2015, 3, 88.	2.4	42
152	<sc>ETV</sc>/Pea3 family transcription factorâ€encoding genes are overexpressed in <sc><i>CIC</i></sc>â€mutant oligodendrogliomas. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 725-733.	1.5	37
153	Expression of far upstream element (FUSE) binding protein 1 in human glioma is correlated with câ€Myc and cell proliferation. <i>Molecular Carcinogenesis</i> , 2015, 54, 405-415.	1.3	46
154	Pathology and Molecular Classification. , 2015, , .		0
155	Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas. <i>Oncotarget</i> , 2015, 6, 43653-43666.	0.8	14
156	The Evolving Molecular Genetics of Low-grade Glioma. <i>Advances in Anatomic Pathology</i> , 2015, 22, 94-101.	2.4	89
157	Genomic Applications in Brain Tumors. , 2015, , 321-339.		0
158	Oligodendroglioma: pathology, molecular mechanisms and markers. <i>Acta Neuropathologica</i> , 2015, 129, 809-827.	3.9	162
160	Biomarker-driven diagnosis of diffuse gliomas. <i>Molecular Aspects of Medicine</i> , 2015, 45, 87-96.	2.7	71
161	Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 694-720.	1.8	83
162	Emerging roles of ATRX in cancer. <i>Epigenomics</i> , 2015, 7, 1365-1378.	1.0	54
163	Oligodendrogliomas: a short history of clinical developments. <i>CNS Oncology</i> , 2015, 4, 281-285.	1.2	4
164	Evidence for involvement of steroid receptors and coactivators in neuroepithelial and meningothelial tumors. <i>Tumor Biology</i> , 2015, 36, 3251-3261.	0.8	10
165	WIPI proteins: essential PtdIns3<i>P</i> effectors at the nascent autophagosome. <i>Journal of Cell Science</i> , 2015, 128, 207-17.	1.2	214
167	Oligodendroglial Tumors. <i>Molecular Pathology Library</i> , 2015, , 105-120.	0.1	0
168	Practical Molecular Pathologic Diagnosis of Infiltrating Gliomas. <i>Surgical Pathology Clinics</i> , 2015, 8, 49-61.	0.7	3
169	The Genetics of Splicing in Neuroblastoma. <i>Cancer Discovery</i> , 2015, 5, 380-395.	7.7	20

#	ARTICLE	IF	CITATIONS
170	Sparse Overlapping Group Lasso for Integrative Multi-Omics Analysis. <i>Journal of Computational Biology</i> , 2015, 22, 73-84.	0.8	18
171	The Biology of Primary Brain Tumors. , 2015, , 573-580.e1.		0
172	Tumor-specific mutations in low-frequency genes affect their functional properties. <i>Journal of Neuro-Oncology</i> , 2015, 122, 461-470.	1.4	13
173	Input of molecular analysis in medical management of primary brain tumor patients. <i>Revue Neurologique</i> , 2015, 171, 457-465.	0.6	2
174	Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 603-606.	1.1	12
175	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. <i>Science Translational Medicine</i> , 2015, 7, 293ra104.	5.8	372
176	Enigmas of IDH mutations in hematology/oncology. <i>Experimental Hematology</i> , 2015, 43, 685-697.	0.2	22
177	Genetic Classification of Gliomas: Refining Histopathology. <i>Cancer Cell</i> , 2015, 28, 9-11.	7.7	40
178	Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9704-9709.	3.3	317
179	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498.	13.9	2,582
180	Isocitrate Dehydrogenase (IDH) Mutation in Gliomas. , 2015, , 441-458.		0
181	Origins of Context-Dependent Gene Repression by Capicua. <i>PLoS Genetics</i> , 2015, 11, e1004902.	1.5	15
182	RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies. <i>Molecular BioSystems</i> , 2015, 11, 2635-2657.	2.9	7
183	Anaplastic glioma: current treatment and management. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 601-620.	1.4	21
184	Next Generation Sequencing in Cancer Research, Volume 2. , 2015, , .		4
185	Molecular Pathways in Gliomagenesis and Their Relevance to Neuropathologic Diagnosis. <i>Advances in Anatomic Pathology</i> , 2015, 22, 50-58.	2.4	78
186	Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies. <i>Journal of Neuro-Oncology</i> , 2015, 123, 373-383.	1.4	14
187	Molecular Classification Defines 4 Prognostically Distinct Glioma Groups Irrespective of Diagnosis and Grade. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 241-249.	0.9	38

#	ARTICLE	IF	CITATIONS
188	Mutational landscape and clonal architecture in grade II and III gliomas. <i>Nature Genetics</i> , 2015, 47, 458-468.	9.4	729
189	Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. <i>Neurology</i> , 2015, 85, 1325-1331.	1.5	34
190	The role of neuropathology in the management of patients with diffuse low grade glioma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 531-549.	1.4	120
191	<i>CIC</i> inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. <i>Annals of Neurology</i> , 2015, 78, 355-374.	2.8	71
192	TCF12 is mutated in anaplastic oligodendroglioma. <i>Nature Communications</i> , 2015, 6, 7207.	5.8	42
193	Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. <i>Nature Structural and Molecular Biology</i> , 2015, 22, 703-711.	3.6	72
194	Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. <i>CNS Oncology</i> , 2015, 4, 287-294.	1.2	48
196	Emerging Interplay of Genetics and Epigenetics in Gliomas: A New Hope for Targeted Therapy. <i>Seminars in Pediatric Neurology</i> , 2015, 22, 14-22.	1.0	12
197	Glioma Biology and Molecular Markers. <i>Cancer Treatment and Research</i> , 2015, 163, 15-30.	0.2	161
198	Current Understanding and Treatment of Gliomas. <i>Cancer Treatment and Research</i> , 2015, , .	0.2	11
199	Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. <i>Head and Neck</i> , 2015, 37, 1642-1649.	0.9	66
200	Genomic Applications in Pathology. , 2015, , .		1
201	Oligoastrocytoma: A Vanishing Tumor Entity. , 0, , .		0
202	Establishment and Biological Characterization of a Panel of Glioblastoma Multiforme (GBM) and GBM Variant Oncosphere Cell Lines. <i>PLoS ONE</i> , 2016, 11, e0150271.	1.1	21
203	Neuropathology of gliomas. , 0, , 146-168.		0
204	Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas. <i>Brain Pathology</i> , 2016, 26, 206-214.	2.1	25
205	Recurrent CIC Gene Abnormalities in Angiosarcomas. <i>American Journal of Surgical Pathology</i> , 2016, 40, 645-655.	2.1	157
206	PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells. <i>Hepatology</i> , 2016, 63, 813-826.	3.6	52

#	ARTICLE	IF	CITATIONS
207	Integrated analysis identified genes associated with a favorable prognosis in oligodendrogliomas. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 169-176.	1.5	3
208	Genetics of glioma. , 0, , 1-23.		1
209	Further understanding of the pathology of glioma: implications for the clinic. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1055-1065.	1.4	32
210	Elevation of Urinary 2-Hydroxyglutarate in <i>IDH</i>-Mutant Glioma. <i>Oncologist</i> , 2016, 21, 214-219.	1.9	33
211	CGCG clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2016, 375, 263-273.	3.2	448
212	Molecular classification of gliomas. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 97-120.	1.0	90
213	Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 620-634.	1.2	42
214	Minibrain and Wings apart control organ growth and tissue patterning through down-regulation of Capicua. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10583-10588.	3.3	26
215	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. <i>Acta Neuropathologica Communications</i> , 2016, 4, 79.	2.4	189
216	Astrocytic gliomas WHO grades II and III. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 345-360.	1.0	11
217	Low-grade and anaplastic oligodendroglioma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 361-380.	1.0	26
218	ZEB1 expression is increased in IDH1-mutant lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2016, 130, 111-122.	1.4	14
219	Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood. <i>Surgical Pathology Clinics</i> , 2016, 9, 379-390.	0.7	4
220	Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells. <i>International Journal of Oncology</i> , 2016, 49, 623-628.	1.4	22
221	Genomic Landscape of Brain Tumors. , 2016, , 653-663.		0
222	Papilloedema secondary to oligodendroglioma. <i>Australasian journal of optometry, The</i> , 2016, 99, 507-517.	0.6	2
223	Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. <i>Nature</i> , 2016, 539, 309-313.	13.7	875
225	IDH mutation is associated with higher risk of malignant transformation in low-grade glioma. <i>Journal of Neuro-Oncology</i> , 2016, 127, 363-372.	1.4	48

#	ARTICLE	IF	CITATIONS
226	Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 497-521.	9.6	37
227	Genotyping low-grade gliomas among Hispanics. Neuro-Oncology Practice, 2016, 3, 164-172.	1.0	4
228	Special Techniques. , 2016, , 11-44.		0
229	Far Upstream Element Binding Protein Plays a Crucial Role in Embryonic Development, Hematopoiesis, and Stabilizing Myc Expression Levels. American Journal of Pathology, 2016, 186, 701-715.	1.9	32
231	Biomarkers Applied to Specific Tumor Types. , 2016, , 59-98.		0
232	The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas. Journal of Neuropathology and Experimental Neurology, 2016, 75, 4-18.	0.9	81
233	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro-Oncology, 2016, 18, 388-400.	0.6	143
234	Isocitrate dehydrogenase mutations in gliomas. Neuro-Oncology, 2016, 18, 16-26.	0.6	221
235	The new WHO 2016 classification of brain tumors—what neurosurgeons need to know. Acta Neurochirurgica, 2017, 159, 403-418.	0.9	85
236	Tumor-Specific Approach: Oligodendroglioma (IDH1 Mutated, 1p/19q Deleted). , 2017, , 251-263.		0
237	ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. Cell Reports, 2017, 18, 1543-1557.	2.9	95
238	CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma. Cancer Research, 2017, 77, 2927-2937.	0.4	85
239	COP9 signalosome subunits protect Capicua from MAP kinase-dependent and independent mechanisms of degradation. Development (Cambridge), 2017, 144, 2673-2682.	1.2	16
240	Genetic and epigenetic stability of oligodendrogliomas at recurrence. Acta Neuropathologica Communications, 2017, 5, 18.	2.4	47
241	A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro-Oncology, 2017, 19, 614-624.	0.6	100
242	Head and Neck Round Cell Sarcomas: A Comparative Clinicopathologic Analysis of 2 Molecular Subsets: Ewing and CIC-Rearranged Sarcomas. Head and Neck Pathology, 2017, 11, 450-459.	1.3	18
243	The expression pattern of long non-coding RNA PVT1 in tumor tissues and in extracellular vesicles of colorectal cancer correlates with cancer progression. Tumor Biology, 2017, 39, 101042831769912.	0.8	44
244	Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome. American Journal of Surgical Pathology, 2017, 41, 941-949.	2.1	278

#	ARTICLE	IF	CITATIONS
245	Comparative transcriptome analysis of isogenic cell line models and primary cancers links capicua (<scp>CIC</scp>) loss to activation of the MAPK signalling cascade. <i>Journal of Pathology</i> , 2017, 242, 206-220.	2.1	31
246	The Effect of Molecular Diagnostics on the Treatment of Glioma. <i>Current Oncology Reports</i> , 2017, 19, 26.	1.8	40
247	Advances in the molecular genetics of gliomas â€” implications for classification and therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 434-452.	12.5	497
248	Primary CIC-DUX4 round cell sarcoma of the kidney: A treatment-refractory tumor with poor outcome. <i>Pathology Research and Practice</i> , 2017, 213, 154-160.	1.0	7
249	A doubleâ€”edged sword: The world according to <i>Capicua</i> in cancer. <i>Cancer Science</i> , 2017, 108, 2319-2325.	1.7	24
250	Isocitrate dehydrogenaseâ€”mutant glioma: Evolving clinical and therapeutic implications. <i>Cancer</i> , 2017, 123, 4535-4546.	2.0	103
251	Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss. <i>Scientific Reports</i> , 2017, 7, 13038.	1.6	5
252	Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma. <i>Genes and Development</i> , 2017, 31, 1456-1468.	2.7	41
253	<i>Cic</i> Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation. <i>Cancer Research</i> , 2017, 77, 6097-6108.	0.4	46
254	Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis. <i>Biochemical and Biophysical Research Communications</i> , 2017, 491, 1047-1054.	1.0	13
255	Recent developments in predictive biomarkers of pediatric glioma. <i>Oncology Letters</i> , 2017, 14, 497-500.	0.8	1
256	Characterization of gliomas: from morphology to molecules. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 257-269.	1.4	86
257	Classification of adult diffuse gliomas by molecular markersâ€”a short review with historical footnote. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 2-6.	0.6	10
259	Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q coâ€”deleted anaplastic gliomas. <i>Brain Pathology</i> , 2017, 27, 567-579.	2.1	16
260	Bathing in carbon dioxide-enriched water alters protein expression in keratinocytes of skin tissue in rats. <i>International Journal of Biometeorology</i> , 2017, 61, 739-746.	1.3	2
261	Inactivation of Capicua drives cancer metastasis. <i>Nature Genetics</i> , 2017, 49, 87-96.	9.4	130
262	Altered capicua transcriptional repressor gene expression exhibits distinct prognostic value for isocitrate dehydrogenase-mutant oligodendroglial tumors. <i>Oncology Letters</i> , 2018, 15, 1459-1468.	0.8	2
263	EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients. <i>Journal of Molecular Cell Biology</i> , 2017, 9, 477-488.	1.5	48

#	ARTICLE	IF	CITATIONS
264	<i>BICD1</i> expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas. <i>Oncotarget</i> , 2017, 8, 113766-113791.	0.8	9
265	Molecular Testing of Brain Tumor. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 205-223.	0.4	56
266	Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics. <i>Advances in Anatomic Pathology</i> , 2018, 25, 143-171.	2.4	31
268	Reconstructing the molecular life history of gliomas. <i>Acta Neuropathologica</i> , 2018, 135, 649-670.	3.9	61
269	Genome-wide CRISPR/Cas9 Screen Identifies Host Factors Essential for Influenza Virus Replication. <i>Cell Reports</i> , 2018, 23, 596-607.	2.9	185
270	Pathology and Genetics of Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 31, 1-37.	1.3	19
271	Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. <i>Progress in Neurological Surgery</i> , 2018, 31, 168-179.	1.3	2
272	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. <i>Neuro-Oncology</i> , 2018, 20, 873-884.	0.6	119
273	The COP9 signalosome inhibits Cullin-RING E3 ubiquitin ligases independently of its deneddylase activity. <i>Fly</i> , 2018, 12, 118-126.	0.9	5
274	Loss of <i>Capicua</i> alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1511-E1519.	3.3	35
275	<i>Capicua</i> suppresses hepatocellular carcinoma progression by controlling the ETV4-MMP1 axis. <i>Hepatology</i> , 2018, 67, 2287-2301.	3.6	70
276	<i>CIC</i> - <i>NUTM1</i> fusion: A case which expands the spectrum of <i>NUT</i> -rearranged epithelioid malignancies. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 446-451.	1.5	53
277	Far Upstream Element-Binding Protein 1 Regulates LSD1 Alternative Splicing to Promote Terminal Differentiation of Neural Progenitors. <i>Stem Cell Reports</i> , 2018, 10, 1208-1221.	2.3	28
278	The <i>Capicua</i> tumor suppressor: a gatekeeper of Ras signaling in development and cancer. <i>Cell Cycle</i> , 2018, 17, 702-711.	1.3	36
279	Astrocytic and Oligodendroglial Tumors. , 2018, , 91-123.		1
280	Survivorship in Neuro-Oncology: Improving Care by Advancing Science. <i>Neuro-Oncology</i> , 2018, 20, NP-NP.	0.6	0
281	Updates in prognostic markers for gliomas. <i>Neuro-Oncology</i> , 2018, 20, vii17-vii26.	0.6	78
282	Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas. <i>Seminars in Oncology Nursing</i> , 2018, 34, 430-442.	0.7	5

#	ARTICLE	IF	CITATIONS
283	Molecular Mechanisms Governing the Stem Cell's Fate in Brain Cancer: Factors of Stemness and Quiescence. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 388.	1.8	41
284	Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. <i>Npj Precision Oncology</i> , 2018, 2, 24.	2.3	32
285	Chromosomal Instability Induces Cellular Invasion in Epithelial Tissues. <i>Developmental Cell</i> , 2018, 47, 161-174.e4.	3.1	32
286	Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1. <i>Biochemical and Biophysical Research Communications</i> , 2018, 505, 830-836.	1.0	10
287	Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts. <i>Acta Neuropathologica Communications</i> , 2018, 6, 95.	2.4	13
288	Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 85.	1.3	9
289	Proteolipid Protein 2 Overexpression Indicates Aggressive Tumor Behavior and Adverse Prognosis in Human Gliomas. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3353.	1.8	25
290	Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation. <i>Nucleic Acids Research</i> , 2018, 46, 11214-11228.	6.5	28
291	Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 804-814.	1.2	22
292	The Tumor Suppressor CIC Directly Regulates MAPK Pathway Genes via Histone Deacetylation. <i>Cancer Research</i> , 2018, 78, 4114-4125.	0.4	56
293	Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 642-645.	2.3	9
294	<i>BCL3</i> expression promotes resistance to alkylating chemotherapy in gliomas. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	52
295	Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults. <i>Neurologic Clinics</i> , 2018, 36, 421-437.	0.8	9
296	Network-based analysis of oligodendrogliomas predicts novel cancer gene candidates within the region of the 1p/19q co-deletion. <i>Acta Neuropathologica Communications</i> , 2018, 6, 49.	2.4	30
297	Importance of genetic background of oxysterol signaling in cancer. <i>Biochimie</i> , 2018, 153, 109-138.	1.3	11
298	<i>IDH</i> -mutated astrocytomas with 19q loss constitute a subgroup that confers better prognosis. <i>Cancer Science</i> , 2018, 109, 2327-2335.	1.7	20
299	Transcriptomic analysis of CIC and ATXN1L reveal a functional relationship exploited by cancer. <i>Oncogene</i> , 2019, 38, 273-290.	2.6	32
300	The pivotal role of sampling recurrent tumors in the precision care of patients with tumors of the central nervous system. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004143.	0.5	4

#	ARTICLE	IF	CITATIONS
301	The crystal structure of Capicua HMGâ€œbox domain complexed with the ETV5â€œDNA and its implications for Capicuaâ€œmediated cancers. FEBS Journal, 2019, 286, 4951-4963.	2.2	7
302	On the Allosteric Effect of nsSNPs and the Emerging Importance of Allosteric Polymorphism. Journal of Molecular Biology, 2019, 431, 3933-3942.	2.0	47
303	Origin and development of oligodendroglioma. , 2019, , 79-87.		0
304	The role of biomarkers in the diagnosis and treatment of oligodendrogliomas. , 2019, , 109-115.		1
305	MYST1/KAT8 contributes to tumor progression by activating EGFR signaling in glioblastoma cells. Cancer Medicine, 2019, 8, 7793-7808.	1.3	18
306	Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas. Cancers, 2019, 11, 1616.	1.7	17
307	Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma. International Journal of Molecular Sciences, 2019, 20, 200.	1.8	30
308	FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis-a new possible marker of malignancy for neuroblastoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 400.	3.5	18
309	Identification of FUBP1 as a Long Tail Cancer Driver and Widespread Regulator of Tumor Suppressor and Oncogene Alternative Splicing. Cell Reports, 2019, 28, 3435-3449.e5.	2.9	32
310	Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors. Neuro-Oncology, 2019, 21, 1164-1174.	0.6	12
311	Transcriptional activation of SIRT6 via FKHL1/FOXO3a inhibits the Warburg effect in glioblastoma cells. Cellular Signalling, 2019, 60, 100-113.	1.7	24
312	Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors. Nature Communications, 2019, 10, 2000.	5.8	34
313	Fubp1 supports the lactate-Akt-mTOR axis through the upregulation of Hk1 and Hk2. Biochemical and Biophysical Research Communications, 2019, 512, 93-99.	1.0	10
314	Pathology of Primary Brain Tumorsâ€œGliomas. , 2019, , 121-137.		2
315	Tumor Genetics and Their Outcomes on Surgery and Survival. , 2019, , 191-203.		0
316	5â€œAzacytidine treatment results in nuclear exclusion of DNA methyltransferaseâ€œ1, as well as reduced proliferation and invasion in human cytomegalovirusâ€œinfected glioblastoma cells. Oncology Reports, 2019, 41, 2927-2936.	1.2	4
317	Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients. BMC Cancer, 2019, 19, 114.	1.1	5
318	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. Neuro-Oncology, 2019, 21, 837-853.	0.6	66

#	ARTICLE	IF	CITATIONS
319	PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4375-4387.	3.2	26
320	<i>Drosophila melanogaster</i> : A Model Organism to Study Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 51.	1.1	158
321	CIC protein instability contributes to tumorigenesis in glioblastoma. <i>Nature Communications</i> , 2019, 10, 661.	5.8	63
322	Canine Primary Intracranial Cancer: A Clinicopathologic and Comparative Review of Glioma, Meningioma, and Choroid Plexus Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 1151.	1.3	63
323	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	13.7	320
324	Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase- mutant Glioma. <i>Clinical Cancer Research</i> , 2019, 25, 1261-1271.	3.2	50
325	Molecular Pathogenesis of Low-Grade Glioma. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 17-25.	0.8	31
326	The master regulator FUBP1: its emerging role in normal cell function and malignant development. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 259-281.	2.4	46
327	Malignant Vascular Tumors of the Liver in Adults. <i>Seminars in Liver Disease</i> , 2019, 39, 001-012.	1.8	9
328	Context is everything: aneuploidy in cancer. <i>Nature Reviews Genetics</i> , 2020, 21, 44-62.	7.7	407
329	Far upstream element-binding protein 1 facilitates hepatocellular carcinoma invasion and metastasis. <i>Carcinogenesis</i> , 2020, 41, 950-960.	1.3	13
330	Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1 mutant and 1p/19q codeleted: a multicenter study from the French POLA network. <i>Brain Pathology</i> , 2020, 30, 465-478.	2.1	20
332	CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1 Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion. <i>JCO Precision Oncology</i> , 2020, 4, 955-971.	1.5	6
333	Oncogenic and Tumor-Suppressive Functions of NOTCH Signaling in Glioma. <i>Cells</i> , 2020, 9, 2304.	1.8	48
334	Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: A Safety Assessment. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 21, 1006-1016.	2.3	16
335	FUBP1 and FUBP2 enforce distinct epigenetic setpoints for MYC expression in primary single murine cells. <i>Communications Biology</i> , 2020, 3, 545.	2.0	8
336	Three-Dimensional Nuclear Telomere Profiling as a Biomarker for Recurrence in Oligodendrogliomas: A Pilot Study. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8539.	1.8	2
337	The Emerging Role of Extracellular Vesicles in the Glioma Microenvironment: Biogenesis and Clinical Relevance. <i>Cancers</i> , 2020, 12, 1964.	1.7	19

#	ARTICLE	IF	CITATIONS
338	TRIM25 promotes Capicua degradation independently of ERK in the absence of ATXN1L. BMC Biology, 2020, 18, 154.	1.7	7
339	Comparative structural analyses and nucleotide-binding characterization of the four KH domains of FUBP1. Scientific Reports, 2020, 10, 13459.	1.6	3
340	miRNA-182 regulated MTSS1 inhibits proliferation and invasion in Glioma Cells. Journal of Cancer, 2020, 11, 5840-5851.	1.2	13
341	<i>CIC de novo</i> loss of function variants contribute to cerebral folate deficiency by downregulating <i>FOLR1</i> expression. Journal of Medical Genetics, 2021, 58, 484-494.	1.5	12
342	Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications. Biomedicines, 2020, 8, 294.	1.4	39
343	Comparative analysis of transcriptomic profile, histology, and IDH mutation for classification of gliomas. Scientific Reports, 2020, 10, 20651.	1.6	6
344	Multiple Functions of Fubp1 in Cell Cycle Progression and Cell Survival. Cells, 2020, 9, 1347.	1.8	6
345	Molecular characteristics of diffuse lower grade gliomas: what neurosurgeons need to know. Acta Neurochirurgica, 2020, 162, 1929-1939.	0.9	10
346	Lower Grade Gliomas. Current Neurology and Neuroscience Reports, 2020, 20, 21.	2.0	68
347	The New CIC Mutation Associates with Mental Retardation and Severity of Seizure in Turkish Child with a Rare Class I Glucose-6-Phosphate Dehydrogenase Deficiency. Journal of Molecular Neuroscience, 2020, 70, 2077-2084.	1.1	3
348	ERK signalling: a master regulator of cell behaviour, life and fate. Nature Reviews Molecular Cell Biology, 2020, 21, 607-632.	16.1	535
349	Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 269-285.	2.3	14
350	Molecular genetics of meningiomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 169, 101-119.	1.0	5
351	Making heads or tails “ the emergence of capicua (CIC) as an important multifunctional tumour suppressor. Journal of Pathology, 2020, 250, 532-540.	2.1	20
352	Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience. Neuro-Oncology Advances, 2020, 2, vdaa009.	0.4	7
353	Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers. International Journal of Molecular Sciences, 2020, 21, 685.	1.8	18
354	Regulation and function of capicua in mammals. Experimental and Molecular Medicine, 2020, 52, 531-537.	3.2	25
355	c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein. Molecular Cancer Research, 2020, 18, 774-786.	1.5	10

#	ARTICLE	IF	CITATIONS
356	Nanotherapy for Brain Tumor Drug Delivery. <i>Neuromethods</i> , 2021, , .	0.2	2
357	Phenotypic Variability of an Inherited Pathogenic Variant in CIC Gene: A New Case Report in Two-Generation Family and Literature Review. <i>Journal of Pediatric Neurology</i> , 2021, 19, 193-201.	0.0	1
358	Capicua in Human Cancer. <i>Trends in Cancer</i> , 2021, 7, 77-86.	3.8	17
359	Approach to the low-grade glioma patient. , 2021, , 136-152.		0
360	IDH-Mutant Astrocytoma With Chromosome 19q13 Deletion Manifesting as an Oligodendroglioma-Like Morphology. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 247-253.	0.9	3
361	Distinct <i>TERT</i> promoter <i>C228T</i> and <i>C250T</i> mutations in a patient with an oligodendroglioma: A case report. <i>Neuropathology</i> , 2021, 41, 236-242.	0.7	2
362	Rare germline variants in the E-cadherin gene <i>CDH1</i> are associated with the risk of brain tumors of neuroepithelial and epithelial origin. <i>Acta Neuropathologica</i> , 2021, 142, 191-210.	3.9	6
363	The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC. <i>Molecular Cancer</i> , 2021, 20, 91.	7.9	49
364	Capicua Regulates Dendritic Morphogenesis Through Ets in Hippocampal Neurons in vitro. <i>Frontiers in Neuroanatomy</i> , 2021, 15, 669310.	0.9	4
365	IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?. <i>Biomedicines</i> , 2021, 9, 799.	1.4	37
366	Multiomics Profiling and Clustering of Low-Grade Gliomas Based on the Integrated Stress Status. <i>BioMed Research International</i> , 2021, 2021, 1-19.	0.9	2
367	Identification of novel autoantibody signatures and evaluation of a panel of autoantibodies in breast cancer. <i>Cancer Science</i> , 2021, 112, 3388-3400.	1.7	9
368	Molecular Pathology of Gliomas. <i>Surgical Pathology Clinics</i> , 2021, 14, 379-386.	0.7	18
369	Activity of Wnt/PCP Regulation Pathway Classifies Patients of Low-Grade Glioma Into Molecularly Distinct Subgroups With Prognostic Difference. <i>Frontiers in Oncology</i> , 2021, 11, 726034.	1.3	3
370	Inorganic Nanostructures for Brain Tumor Management. <i>Neuromethods</i> , 2021, , 145-178.	0.2	4
371	Dynamics of DLGG and Clinical Implications. , 2013, , 249-262.		1
372	Adult High-Grade (Diffuse) Glioma. <i>Molecular Pathology Library</i> , 2015, , 77-93.	0.1	2
373	Epidemiology of Diffuse Low Grade Gliomas. , 2017, , 13-53.		11

#	ARTICLE	IF	CITATIONS
374	Molecular-Genetic Classification of Gliomas and Its Practical Application to Diagnostic Neuropathology. , 2017, , 73-100.		2
379	CIC is a critical regulator of neuronal differentiation. JCI Insight, 2020, 5, .	2.3	21
380	Capicua suppresses colorectal cancer progression via repression of ETV4 expression. Cancer Cell International, 2020, 20, 42.	1.8	16
381	DNA Extraction and Purification. Materials and Methods, 0, 3, .	0.0	25
382	PCR Machines. Materials and Methods, 0, 3, .	0.0	1
383	EGFR/Ras Signaling Controls Drosophila Intestinal Stem Cell Proliferation via Capicua-Regulated Genes. PLoS Genetics, 2015, 11, e1005634.	1.5	115
384	A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer. PLoS Genetics, 2017, 13, e1006622.	1.5	45
385	The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers. PLoS ONE, 2013, 8, e55119.	1.1	458
386	Upregulation of Far Upstream Element-Binding Protein 1 (FUBP1) Promotes Tumor Proliferation and Tumorigenesis of Clear Cell Renal Cell Carcinoma. PLoS ONE, 2017, 12, e0169852.	1.1	29
387	Genetic landscape of extreme responders with anaplastic oligodendroglioma. Oncotarget, 2017, 8, 35523-35531.	0.8	8
388	ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples. Oncotarget, 2014, 5, 2551-2561.	0.8	61
389	Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. Oncotarget, 2014, 5, 7960-7979.	0.8	35
390	Deep sequencing of a recurrent oligodendroglioma and the derived xenografts reveals new insights into the evolution of human oligodendroglioma and candidate driver genes. Oncotarget, 2019, 10, 3641-3653.	0.8	1
391	â€ˆCut from the same clothâ€™: Shared microsatellite variants among cancers link to ectodermal tissues-neural tube and crest cells. Oncotarget, 2015, 6, 22038-22047.	0.8	7
392	Exomic Sequencing of Four Rare Central Nervous System Tumor Types. Oncotarget, 2013, 4, 572-583.	0.8	69
393	Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis. Cancer Biology and Medicine, 2019, 16, 784-796.	1.4	25
394	Receptor tyrosine kinase expression in highâ€™grade gliomas before and after chemoradiotherapy. Oncology Letters, 2019, 18, 6509-6515.	0.8	3
395	From the bench to the bedside: Genetics of intellectual disability, Gustatopic mapping, Molecular origins of oligodendrogliomas, Back pain and the brain, and moreâ€™. , 2011, 2, 172.		0

#	ARTICLE	IF	CITATIONS
396	Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma. Yearbook of Neurology and Neurosurgery, 2012, 2012, 101-102.	0.0	0
397	Genomic Alterations in Sporadic Pancreatic Cancer. , 2013, , 1-26.		0
398	Extraction et purification de l'ADN. Materials and Methods, 0, fr3, .	0.0	1
399	Software Programs in Biomedical Research. Materials and Methods, 0, 3, .	0.0	0
400	How to Use Molecular Markers When Caring for a Patient with Brain Cancer: 1P/19Q as a Predictive and Prognostic Marker in the Neuro-oncology Clinic. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 114-116.	1.8	0
401	FUBP1 (far upstream element (FUSE) binding protein 1). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2013, , .	0.1	0
403	Molecular Testing in CNS tumors. , 2014, , 243-255.		0
404	LGR5 as a Marker in Brain Cancer. , 2014, , 1-14.		0
405	LGR5 as Marker in Brain Cancer. Biomarkers in Disease, 2015, , 361-378.	0.0	0
406	Integrated Diagnostic Approach for Adult Oligodendroglioma and Oligoastrocytoma. Brain Disorders & Therapy, 2015, 04, .	0.1	2
407	CIC Mutation as Signature Alteration in Oligodendroglioma. , 2015, , 423-440.		0
408	Refined Glioma Classification based on Molecular Pathology. Japanese Journal of Neurosurgery, 2015, 24, 366-377.	0.0	0
409	Oligodendroglioma. , 2016, , 8-394-8-397.		0
410	Translating Molecular Biomarkers of Gliomas to Clinical Practice. , 2016, , 33-53.		0
411	Hirntumoren. Springer-Lehrbuch, 2016, , 311-365.	0.1	1
413	Oligodendroglioma. , 2017, , 3192-3196.		0
414	The Genomics of Diffuse Low-Grade Gliomas. , 2017, , 137-149.		0
415	Dynamics of DLGG and Clinical Implications. , 2017, , 287-306.		0

#	ARTICLE	IF	CITATIONS
417	High-Grade Gliomas. , 2018, , 83-102.		0
418	Low-Grade Glioma. , 2018, , 65-82.		0
419	Genomic Applications in Brain Tumors. , 2019, , 289-308.		0
422	Mouse Models of Diffuse Lower-Grade Gliomas of the Adult. <i>NeuroMethods</i> , 2021, , 3-38.	0.2	0
423	Deletion Timing of <i>Cic</i> Alleles during Hematopoiesis Determines the Degree of Peripheral CD4 ⁺ T Cell Activation and Proliferation. <i>Immune Network</i> , 2020, 20, e43.	1.6	7
424	Integrating real-time in vivo tumour genomes for longitudinal analysis and management of glioma recurrence. <i>Clinical and Translational Medicine</i> , 2021, 11, e567.	1.7	3
425	A mathematical model for short-term vs. long-term survival in patients with glioma. <i>American Journal of Cancer Research</i> , 2014, 4, 862-73.	1.4	8
426	High copy number of mitochondrial DNA (mtDNA) predicts good prognosis in glioma patients. <i>American Journal of Cancer Research</i> , 2015, 5, 1207-16.	1.4	17
427	A review of gliomas-related proteins. Characteristics of potential biomarkers. <i>American Journal of Cancer Research</i> , 2021, 11, 3425-3444.	1.4	1
428	T-cell Receptor Therapy Targeting Mutant <i>Capicua</i> Transcriptional Repressor in Experimental Gliomas. <i>Clinical Cancer Research</i> , 2022, 28, 378-389.	3.2	11
429	Integrative multi-omic analysis reveals neurodevelopmental gene dysregulation in <i>Cic</i> knockout and <i>IDH1</i> mutant cells. <i>Journal of Pathology</i> , 2022, 256, 297-309.	2.1	5
430	<i>Cic</i> -Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma. <i>Cancer Research</i> , 2022, 82, 1110-1127.	0.4	3
432	Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch. <i>CNS Oncology</i> , 2022, 11, CNS83.	1.2	5
434	Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. <i>Brain Pathology</i> , 2022, 32, e13062.	2.1	53
435	Non-Canonical NF- κ B Signaling Stratifies LGG into Subtypes with Distinct Molecular and Cellular Characteristic and Survival Expectancy. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3677-3686.	0.8	0
436	<i>PIMREG</i> expression level predicts glioblastoma patient survival and affects temozolomide resistance and DNA damage response. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166382.	1.8	3
438	A Novel <i>TNFSF</i> -Based Signature Predicts the Prognosis and Immunosuppressive Status of Lower-Grade Glioma. <i>BioMed Research International</i> , 2022, 2022, 1-21.	0.9	1
439	Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens. <i>Human Pathology</i> , 2022, 126, 63-76.	1.1	5

#	ARTICLE	IF	CITATIONS
440	Integrated proteomic analysis of low-grade gliomas reveals contributions of 1p-19q co-deletion to oligodendroglioma. <i>Acta Neuropathologica Communications</i> , 2022, 10, 70.	2.4	4
441	CIC-DUX4 sarcomas. <i>Current Opinion in Oncology</i> , 2022, 34, 342-347.	1.1	4
442	Current and Future Frontiers of Molecularly Defined Oligodendrogliomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
443	Noncanonical function of Capicua as a growth termination signal in <i>Drosophila</i> oogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	0
444	IGFBPs were associated with stemness, inflammation, extracellular matrix remodeling and poor prognosis of low-grade glioma. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	5
445	Generation of chromosome 1p/19q co-deletion by CRISPR/Cas9-guided genomic editing. <i>Neuro-Oncology Advances</i> , 0, , .	0.4	1
446	Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	39
447	FBP1 knockdown decreases ovarian cancer formation and cisplatin resistance through EZH2-mediated H3K27me3. <i>Bioscience Reports</i> , 2022, 42, .	1.1	3
448	The role of Calmodulin Binding Transcription Activator 1 (<i>CAMTA1</i>) gene and its putative genetic partners in the human nervous system. <i>Psychogeriatrics</i> , 2022, 22, 869-878.	0.6	1
449	Exosome-based strategies for diagnosis and therapy of glioma cancer. <i>Cancer Cell International</i> , 2022, 22, .	1.8	16
450	<i>CIC</i> missense variants contribute to susceptibility for spina bifida. <i>Human Mutation</i> , 2022, 43, 2021-2032.	1.1	1
451	Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. <i>Cell Genomics</i> , 2022, 2, 100179.	3.0	74
452	Small round cell sarcomas. <i>Nature Reviews Disease Primers</i> , 2022, 8, .	18.1	9
453	Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. <i>Neuro-Oncology</i> , 2023, 25, 4-25.	0.6	45
456	Estimating the Prognosis of Low-Grade Glioma with Gene Attention Using Multi-Omics and Multi-Modal Schemes. <i>Biology</i> , 2022, 11, 1462.	1.3	9
457	Clinical and Translational Advances in Glioma Immunotherapy. <i>Neurotherapeutics</i> , 2022, 19, 1799-1817.	2.1	14
458	Genetic Inactivation of Notch1 Synergizes with Loss of Trp53 to Induce Tumor Formation in the Adult Mouse Forebrain. <i>Cancers</i> , 2022, 14, 5409.	1.7	0
459	CIC-Rearranged Sarcomas: An Intriguing Entity That May Lead the Way to the Comprehension of More Common Cancers. <i>Cancers</i> , 2022, 14, 5411.	1.7	5

#	ARTICLE	IF	CITATIONS
460	The CIC-ERF co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression. <i>ELife</i> , 0, 11, .	2.8	3
461	Stromal protein CCN family contributes to the poor prognosis in lower-grade glioma by modulating immunity, matrix, stemness, and metabolism. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	2
462	CIC reduces xCT/SLC7A11 expression and glutamate release in glioma. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	4
463	Preclinical Models of Low-Grade Gliomas. <i>Cancers</i> , 2023, 15, 596.	1.7	4
464	Genomic Profiling of Lower-Grade Gliomas Subtype with Distinct Molecular and Clinicopathologic Characteristics via Altered DNA-Damage Repair Features. <i>Journal of Molecular Neuroscience</i> , 2023, 73, 269-286.	1.1	0
466	Prognostic RNA-editing signature predicts immune functions and therapy responses in gliomas. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
468	Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	3
469	Metabolic Rewiring in Adult-Type Diffuse Gliomas. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7348.	1.8	2
476	Journal of Neuro Oncology: Diagnostic and therapeutic implications of IDH mutations in gliomas following the 2021 World Health Organization classification of CNS tumors. <i>Journal of Neuro-Oncology</i> , 2023, 162, 457-459.	1.4	1
477	Neuroimaging of Brain Tumors in the Era of Radiogenomics. , 2023, , 1275-1311.		0
479	Liquid biopsy: creating opportunities in brain space. <i>British Journal of Cancer</i> , 2023, 129, 1727-1746.	2.9	1